Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

47.51 -0.72 (-1.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
News headline image
Flu Season's Here—This Dividend-Payer Controls the Shot Market ↗
Via MarketBeat
Topics Artificial Intelligence Death
News headline image
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance
In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report ↗
Drugmakers are outlining 2026 list price changes, with most adjustments typically announced in January. 
Via Stocktwits
Topics Economy Government
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme... 
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
The Dynavax Turnaround: From Clinical Setbacks to a $2.2 Billion Exit
As of December 26, 2025, the biotechnology landscape is processing one of the most significant mid-cap acquisitions of the year. Dynavax Technologies Corporation (NASDAQ: DVAX) has transitioned from a... 
Via PredictStreet
News headline image
The Great Vaccine Consolidation: Sanofi’s $2.2 Billion Strategic Bet on Dynavax Technologies
Dateline: December 25, 2025 Introduction In a move that has sent shockwaves through the biotechnology and pharmaceutical sectors on this Christmas Day, the global vaccine landscape has been... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax
As 2025 draws to a close, the global pharmaceutical landscape has been reshaped by a series of aggressive consolidations and strategic pivots. At the center of this transformation is Sanofi (NASDAQ:... 
Via PredictStreet
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Why Dynavax Stock Soared Today ↗
A healthcare titan wants to buy the biotech's vaccines. 
Via The Motley Fool
News headline image
Sanofi’s $2.2 Billion Strategic Pivot: Deconstructing the Dynavax Acquisition and the Future of Specialty Medicine
As of today, December 24, 2025, the global pharmaceutical landscape is witnessing a profound consolidation of power within specialty medicine and immunology. Sanofi (NASDAQ: SNY; Euronext: SAN), the... 
Via PredictStreet
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Dynavax Technologies: Analyzing the 39% Surge and Sanofi Acquisition
Introduction On December 24, 2025, the biotechnology sector received its most significant holiday gift in years. Sanofi (NASDAQ: SNY; Euronext: SAN) announced a definitive agreement to acquire Dynavax... 
Via PredictStreet
Topics Economy
News headline image
Sanofi Acquires Dynavax in $2.2 Billion Christmas Eve Deal, Sending Shares Soaring
In a blockbuster conclusion to the 2025 trading year, Dynavax Technologies (NASDAQ:DVAX) saw its stock price skyrocket by nearly 40% in premarket trading this morning, December 24, 2025. The surge... 
Via MarketMinute
Topics Intellectual Property
News headline image
Why Did Dynavax Stock Surge 38% In Premarket Today? ↗
French drugmaker Sanofi agreed to acquire vaccine maker Dynavax in a $2.2 billion deal. 
Via Stocktwits
Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗
Via Stocktwits
Topics Government
News headline image
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗
The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief. 
Via Stocktwits
Topics Government World Trade
News headline image
Is Alnylam Pharmaceuticals a Millionaire Maker? ↗
This hot biotech stock could have a lot more room to run. 
Via The Motley Fool
News headline image
Moderna, BioNTech Slammed After FDA Links Covid Shots To 10 Deaths ↗
Moderna tumbled Monday after an FDA director reportedly issued a memo that says Covid shots killed 10 children. 
Via Investor's Business Daily
Topics Death
News headline image
Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? ↗
The comeback may have begun. 
Via The Motley Fool
News headline image
Sanofi Stock Drops After Confirming Raid, Tax Fraud Investigation ↗
Sanofi stock dropped Wednesday after French authorities raided the firm's headquarters as part of a tax fraud investigation. 
Via Investor's Business Daily
Topics Fraud
News headline image
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
AI Revolutionizes Drug Shelf-Life: Optimized Stability Models Promise Safer, More Effective Medicines
The pharmaceutical industry is on the cusp of a profound transformation, driven by the integration of data science and Artificial Intelligence (AI) into drug formulation stability models. This... 
Via TokenRing AI
Topics Artificial Intelligence Economy Product Recall
News headline image
Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025
The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Why Roche Holding Stock Popped Today ↗
Roche is great at developing drugs -- but is its stock a great buy? 
Via The Motley Fool
News headline image
TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results ↗
Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on rival TG Therapeutics. 
Via Investor's Business Daily
News headline image
Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60% ↗
Merck said Saturday its new pill — a possible rival to Regeneron and Amgen — lowered high cholesterol by almost 60%. 
Via Investor's Business Daily
News headline image
AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns
Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design... 
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
News headline image
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio
The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
News headline image
Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness ↗
Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea sales. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.